Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein Folding Quality Check in the RER01:29

Protein Folding Quality Check in the RER

4.4K
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
4.4K
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
ER Retrieval Pathway01:45

ER Retrieval Pathway

3.8K
In the secretory pathway, vesicles transport proteins from one cellular compartment to another in forward transport to deliver the protein to its correct location. Occasionally, misfolded proteins and incorrect proteins escape their original compartments, and a retrieval pathway is used to return the escaped proteins to their original compartment.
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
3.8K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines for geriatric oncology in India: Recommendations for clinical practice (version 1).

Journal of geriatric oncology·2026
Same author

Microenvironmental Cues That Regulate Cancer Cell Dormancy in Estrogen-Receptor Positive and Triple-Negative Breast Cancer Cell Lines.

Cancer medicine·2026
Same author

"Assessment of an EMR-integrated Onco-Insight hospital-based cancer registry system for data completeness and data entry turnaround time at a tertiary care cancer center in India".

Frontiers in oncology·2026
Same author

Alpelisib enhances cisplatin mediated cytotoxicity in non-mutated, PIK3CA-dependent high-grade serous ovarian cancer.

Journal of ovarian research·2026
Same author

Authors' Response.

The Indian journal of medical research·2026
Same author

Hypoxia-reoxygenation cycle leads to context dependent phenotypic effects in breast cancer cell lines.

Molecular biology reports·2026

Related Experiment Video

Updated: May 1, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.5K

Eribulin drug review.

Nishitha Shetty1, Sudeep Gupta1

  • 1Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.

South Asian Journal of Cancer
|March 26, 2014
PubMed
Summary
This summary is machine-generated.

Eribulin mesylate is a life-saving anticancer drug derived from a marine sponge, effective for metastatic breast cancer resistant to other treatments. Ongoing trials explore its potential in various other refractory tumors.

Keywords:
Eribulinbreast chemotherapytaxane

More Related Videos

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
05:57

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays

Published on: April 26, 2024

1.6K
Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
07:35

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

23.2K

Related Experiment Videos

Last Updated: May 1, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.5K
Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
05:57

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays

Published on: April 26, 2024

1.6K
Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
07:35

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

23.2K

Area of Science:

  • Oncology
  • Pharmacology
  • Marine Biotechnology

Background:

  • Eribulin mesylate is a synthetic macrocyclic ketone analog of halichondrin B, originally isolated from the marine sponge Halichondria okadai.
  • It is approved for patients with metastatic breast cancer who have progressed on anthracyclines and taxanes.
  • Eribulin functions as a microtubule dynamics inhibitor, leading to prolonged mitotic arrest and apoptosis.

Purpose of the Study:

  • To review the efficacy and safety of eribulin mesylate in metastatic breast cancer.
  • To discuss its mechanism of action and potential applications in other malignancies.

Main Methods:

  • Review of clinical trial data and scientific literature on eribulin mesylate.
  • Analysis of its pharmacokinetic and pharmacodynamic properties.
  • Evaluation of its role in various cancer types.

Main Results:

  • Eribulin demonstrates significant efficacy in heavily pre-treated metastatic breast cancer patients.
  • Common adverse events include neutropenia, neuropathy, and QT prolongation.
  • Phase I/II trials are investigating eribulin in lung, ovarian, pancreatic, bladder, and soft tissue tumors.

Conclusions:

  • Eribulin mesylate is a valuable therapeutic option for refractory metastatic breast cancer.
  • Its potential utility in a broader range of solid tumors is under active investigation.
  • Further prospective studies are crucial to establish its role in diverse oncological settings.